Europe Antibody Drug Conjugates (ADC) Market to 2032
Overview
The Europe Antibody Drug Conjugates (ADC) Market is expected to reach a 9.76 USD Billion by 2032 and is projected to grow at a CAGR of 18.84% from 2025 to 2032.
Revenue, 2024 (USD Billion)
2.91
Forecast, 2032 (USD Billion)
9.76
CAGR, 2024 - 2032
18.84%
Report Coverage
Europe
Europe Antibody Drug Conjugates (ADC) Market 2018-2032 USD Billion
Europe Antibody Drug Conjugates (ADC) Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 2.91 USD Billion
- Projected Market Size (2032): 9.76 USD Billion
- CAGR (2025-2032): 18.84%
Key Findings of Europe Antibody Drug Conjugates (ADC) Market
- The Europe Antibody Drug Conjugates (ADC) Market was valued at 9.76 USD Billion in 2024.
- The Europe Antibody Drug Conjugates (ADC) Market is likely to grow at a CAGR of 18.84% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Cleavable Linkers in Linkers Component Segment accounted for the largest share of the market with a revenue of 2.31 USD Billion
- The fastest growing segment Ambulatory Centers in End User Segment grew Fastest with a CAGR of 20.21% during the forecast period from 2024 to 2032.
Europe Antibody Drug Conjugates (ADC) Market Scope
Europe Antibody Drug Conjugates (ADC) Market Segmentation & Scope
Product
- Tivdak
- Mylotarg
- Zylonta
- Elahere
- Besponsa
- Others
- Padcev
- Adcetris
- Polivy
- Trodelvy
- Kadcyla
- Enhertu
Antigen Component
- Tissue Factors
- CD33
- CD19
- Others
- CD22
- Nectin 4
- CD30
- CD79B
- Trop-2
- HER2 Receptor
Distribution Channel
- Others
- Retail Sales
- Direct Tenders
End User
- Home Healthcare
- Others
- Ambulatory Centers
- Clinics
- Specialty Center
- Hospitals
Indication
- Others
- Genitourinary Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Lung Cancer
- Blood Cancer (Leukemia, Lymphoma)
- Breast Cancer
Linkers Component
- Non Cleavable Linkers
- Cleavable Linkers
Antibody Component
- First Generation ADCs
- Fourth Generation ADCs
- Second Generation ADCs
- Third Generation ADCs
Cytotoxic Payloads or Warheads Component
- Microtubule Disrupting Agents
- DNA Damaging Agents
Conjugation Technology
- Chemical Conjugation
- Site-Specific Conjugation
Linker Technology
- Disulfide Linkers
- Hydrazone Linkers
- Thioether Linkers
- Peptide Linkers
Europe Antibody Drug Conjugates (ADC) Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2023 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 2.91 USD Billion |
| Market Value in 2032 | 9.76 USD Billion |
| CAGR (2025-2032) | 18.84% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Product,Antigen Component,Distribution Channel,End User,Indication,Linkers Component,Antibody Component,Cytotoxic Payloads or Warheads Component,Conjugation Technology,Linker Technology |
Regional Insights:
-
Leading Market (2024-2032): Europe, leading in terms of revenue 2.91 USD Billion in 2024
- Key Country: Germany, leading in terms of revenue with value of 598.28 USD Million in 2024.
Segments and Scope
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Product
- Enhertu is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.03 USD Billion in the year 2024.
- Enhertu is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 20.09 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Antigen Component
- HER2 Receptor is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.73 USD Billion in the year 2024.
- HER2 Receptor is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 19.28 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Distribution Channel
- Direct Tenders is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.93 USD Billion in the year 2024.
- Retail Sales is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 18.87 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By End User
- Hospitals is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.74 USD Billion in the year 2024.
- Ambulatory Centers is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 18.39 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Indication
- Breast Cancer is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.23 USD Billion in the year 2024.
- Breast Cancer is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 19.57 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Linkers Component
- Cleavable Linkers is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 2.31 USD Billion in the year 2024.
- Cleavable Linkers is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 18.88 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Antibody Component
- Third Generation ADCs is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.63 USD Billion in the year 2024.
- Third Generation ADCs is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 19.03 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Cytotoxic Payloads or Warheads Component
- DNA Damaging Agents is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.82 USD Billion in the year 2024.
- DNA Damaging Agents is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 18.93 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Conjugation Technology
- Site-Specific Conjugation is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.63 USD Billion in the year 2024.
- Site-Specific Conjugation is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 19.38 % in forecast period 2025-2032.
-
Europe Antibody Drug Conjugates (ADC) Market to 2032, By Linker Technology
- Peptide Linkers is the largest segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 1.78 USD Billion in the year 2024.
- Peptide Linkers is the Fastest growing segment in Europe Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 18.94 % in forecast period 2025-2032.
Europe Antibody Drug Conjugates (ADC) Market Company Share Analysis
| Company Name |
|
||
| Takeda Pharmaceutical Company Limited | |||
| Astellas Pharma Inc. | |||
| Gilead Sciences, Inc. | |||
| DAIICHI SANKYO COMPANY, LIMITED | |||
| F. Hoffmann-La Roche Ltd. | |||
Europe Antibody Drug Conjugates (ADC) Market Geographical Sales Distribution, 2018-2032 USD Billion
Europe Antibody Drug Conjugates (ADC) Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Europe Antibody Drug Conjugates (ADC) Market is segmented based on Segmentation Product,Antigen Component,Distribution Channel,End User,Indication,Linkers Component,Antibody Component,Cytotoxic Payloads or Warheads Component,Conjugation Technology,Linker Technology.
Europe Antibody Drug Conjugates (ADC) Market was valued at USD 2.91(Revenue in USD Billion) in 2023.
Europe Antibody Drug Conjugates (ADC) Market is projected to grow at a CAGR of 18.84% during the forecast period of 2024 to 2032.
The Cleavable Linkers segment is expected to dominate the Europe Antibody Drug Conjugates (ADC) Market, holding a largest market share of 2.31 USD Billion in 2024
Europe Antibody Drug Conjugates (ADC) Market Scope
Europe Antibody Drug Conjugates (ADC) Market Segmentation & Scope
Product
- Tivdak
- Mylotarg
- Zylonta
- Elahere
- Besponsa
- Others
- Padcev
- Adcetris
- Polivy
- Trodelvy
- Kadcyla
- Enhertu
Antigen Component
- Tissue Factors
- CD33
- CD19
- Others
- CD22
- Nectin 4
- CD30
- CD79B
- Trop-2
- HER2 Receptor
Distribution Channel
- Others
- Retail Sales
- Direct Tenders
End User
- Home Healthcare
- Others
- Ambulatory Centers
- Clinics
- Specialty Center
- Hospitals
Indication
- Others
- Genitourinary Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Lung Cancer
- Blood Cancer (Leukemia, Lymphoma)
- Breast Cancer
Linkers Component
- Non Cleavable Linkers
- Cleavable Linkers
Antibody Component
- First Generation ADCs
- Fourth Generation ADCs
- Second Generation ADCs
- Third Generation ADCs
Cytotoxic Payloads or Warheads Component
- Microtubule Disrupting Agents
- DNA Damaging Agents
Conjugation Technology
- Chemical Conjugation
- Site-Specific Conjugation
Linker Technology
- Disulfide Linkers
- Hydrazone Linkers
- Thioether Linkers
- Peptide Linkers
Frequently Asked Questions
The Europe Antibody Drug Conjugates (ADC) Market is segmented based on Segmentation Product,Antigen Component,Distribution Channel,End User,Indication,Linkers Component,Antibody Component,Cytotoxic Payloads or Warheads Component,Conjugation Technology,Linker Technology.
Europe Antibody Drug Conjugates (ADC) Market was valued at USD 2.91(Revenue in USD Billion) in 2023.
Europe Antibody Drug Conjugates (ADC) Market is projected to grow at a CAGR of 18.84% during the forecast period of 2024 to 2032.
The estimated market value of the Europe Antibody Drug Conjugates (ADC) Market for final year is USD 9.76 (USD Billion).
Europe Antibody Drug Conjugates (ADC) Market Company Profiling
Frequently Asked Questions
The Europe Antibody Drug Conjugates (ADC) Market is segmented based on Segmentation Product,Antigen Component,Distribution Channel,End User,Indication,Linkers Component,Antibody Component,Cytotoxic Payloads or Warheads Component,Conjugation Technology,Linker Technology.
Europe Antibody Drug Conjugates (ADC) Market was valued at USD 2.91(Revenue in USD Billion) in 2023.
Europe Antibody Drug Conjugates (ADC) Market is projected to grow at a CAGR of 18.84% during the forecast period of 2024 to 2032.
The estimated market value of the Europe Antibody Drug Conjugates (ADC) Market for final year is USD 9.76 (USD Billion).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.